Hepatitis b - modes of transmission ,prevention and control . For 5 marks university question minimum 3 handwritten pages . Source:park textbook

Your credits are exhausted. You can purchase a top-up or subscribe to a plan to continue using Orris. If you're already subscribed, your daily credits will reset tomorrow.

Hepatitis b - modes of transmission ,prevention and control . For 5 marks university question minimum 3 handwritten pages . Source:park textbook

Reading File

Finding Sources

Reading File

I now have all the content needed from Park's textbook. Let me compile the comprehensive answer.

HEPATITIS B - Modes of Transmission, Prevention and Control

(Park's Textbook of Preventive and Social Medicine)

INTRODUCTION

Hepatitis B (formerly called "serum hepatitis") is an acute systemic infection with major pathology in the liver, caused by the Hepatitis B Virus (HBV). It can present as acute or chronic infection, ranging from asymptomatic to severe fulminant hepatitis. The case fatality rate of acute hepatitis B is 0.5 to 1%. Chronic HBV infection is defined as persistent HBV infection with or without active viral replication and evidence of hepatocellular injury.

CAUSATIVE AGENT

Hepatitis B Virus (HBV) - a double-stranded DNA virus (Hepadnavirus family)
Key antigens: HBsAg (surface antigen - marker of infection), HBeAg (marker of infectivity and active replication), HBcAg (core antigen)
HBV is 50-100 times more infectious than HIV
The virus survives outside the body for at least 7 days on environmental surfaces

MODES OF TRANSMISSION

HBV is present in high concentrations in blood and serous exudates, and in moderate concentrations in semen, vaginal fluid, and saliva. Transmission occurs via three main routes:

1. Parenteral (Blood-borne) Transmission

Blood transfusion with HBsAg-positive blood or blood products
Needle sharing among intravenous (IV) drug users - a major route in developed countries
Contaminated syringes and needles in medical/dental settings (nosocomial transmission)
Needlestick injuries among healthcare workers
Tattooing, ear/body piercing, acupuncture with unsterilized equipment
Dialysis patients (haemodialysis units are a high-risk setting)
Sharing razors or other personal items contaminated with blood

2. Sexual Transmission (Horizontal)

Unprotected sexual intercourse (both heterosexual and homosexual)
HBV is found in semen and vaginal secretions
Multiple sexual partners significantly increases risk
Sexually transmitted HBV is responsible for a large proportion of infections in low-endemicity countries

3. Perinatal (Vertical) Transmission - Mother to Child

From HBsAg-positive mother to infant at the time of birth (perinatal transmission)
Risk is highest when the mother is both HBsAg and HBeAg positive (up to 70-90% risk of transmission without prophylaxis)
Transmission occurs mainly during delivery (exposure to maternal blood/secretions), NOT usually transplacentally
This is the most common route in highly endemic areas (Southeast Asia, Africa)
Infection acquired perinatally carries >90% risk of progressing to chronic HBV

4. Close (Horizontal) Household Transmission

Transmission through close personal contact within households among young children
Via minor cuts, skin abrasions, or shared personal items (toothbrushes, razors)
Common in hyperendemic areas and crowded living conditions
Mucous membrane exposure to infected secretions

Note: HBV is NOT transmitted by the faecal-oral route (unlike Hepatitis A), contaminated food/water, sneezing, coughing, or casual contact.

EPIDEMIOLOGICAL DETERMINANTS

Factor	Details
Agent	HBV - DNA virus, Hepadnaviridae
Incubation period	45-180 days (average 60-90 days)
Infectious period	Weeks before onset of symptoms through acute phase; indefinitely in chronic carriers
HBsAg prevalence	≥8% = highly endemic; 2-4% = low intermediate; <2% = low endemic
Global burden	~257 million with chronic HBV (2015); ~887,000 deaths/year

PREVENTION AND CONTROL

Prevention of HBV involves a combination of specific (immunological) and non-specific measures.

A. SPECIFIC PROPHYLAXIS

(i) Hepatitis B Vaccine (Active Immunization)

The hepatitis B vaccine is the cornerstone of HBV prevention.

Types of vaccine:

Recombinant DNA vaccine (currently used) - contains purified HBsAg produced by recombinant DNA technology in yeast cells (Saccharomyces cerevisiae) - safe and highly effective
Earlier: plasma-derived vaccine (no longer widely used)

Schedule (as per National Immunization Schedule - India):

Birth dose - within 24 hours of birth (critical for preventing perinatal transmission)
6 weeks, 10 weeks, 14 weeks - given as part of Pentavalent vaccine (DPT + HBV + Hib)
Total: 4 doses (0, 6, 10, 14 weeks)

Why the birth dose must be given within 24 hours: The birth dose is effective in preventing perinatal transmission of HBV only if given within the first 24 hours of birth. Delaying the birth dose reduces its protective efficacy. The birth dose should ideally be given before the infant leaves the birthing facility.

Dose and route:

Neonates/Children: 10 mcg IM (anterolateral thigh)
Adults: 20 mcg IM (deltoid)
Route: Intramuscular (NOT subcutaneous or intradermal for standard schedule)

Efficacy: 90-95% effective in preventing HBV infection and its chronic consequences. Antibody levels (Anti-HBs) of ≥10 mIU/mL indicate protection.

Booster doses: Not routinely recommended for immunocompetent individuals who completed the primary series and showed adequate seroresponse.

Special groups requiring vaccination:

Newborns of HBsAg-positive mothers
Healthcare workers
Haemodialysis patients
Sexual partners of HBV-infected persons
IV drug users
Persons with multiple sexual partners

(ii) Hepatitis B Immunoglobulin (HBIG) - Passive Immunization

HBIG provides immediate but temporary protection (passive immunity).

Indications for HBIG:

Newborns of HBsAg-positive mothers - given simultaneously with first dose of HBV vaccine but at different sites (combined prophylaxis gives >95% protection against perinatal transmission)
Post-exposure prophylaxis in unvaccinated or incompletely vaccinated individuals after:
- Needlestick injury with HBsAg-positive blood
- Sexual exposure to HBsAg-positive person
- Accidental mucous membrane/open wound exposure

Dose: 0.06 mL/kg body weight IM, given as soon as possible (ideally within 12-24 hours; up to 7 days for sexual exposure, up to 14 days for needlestick)

Combined (active + passive) prophylaxis for neonates of HBsAg-positive mothers: HBIG + HBV vaccine given simultaneously at different sites within 12 hours of birth - this is the most effective strategy.

B. NON-SPECIFIC (GENERAL) PREVENTION MEASURES

1. Blood Safety

Screening of all blood donors for HBsAg before transfusion - mandatory
Use of HBsAg-negative blood only for transfusion
Promotion of voluntary blood donation
Avoid unnecessary blood transfusions
NAT (Nucleic Acid Testing) for additional safety in blood banks

2. Safe Injection Practices

Use of sterile, disposable syringes and needles for every injection
Never reuse needles/syringes
Proper needle disposal in puncture-proof containers
Needle exchange programs for IV drug users
Promotion of auto-disable (AD) syringes to prevent reuse

3. Prevention of Sexual Transmission

Safe sex practices - consistent use of condoms
Reducing number of sexual partners
Screening and counselling of sex workers
Routine screening of sexually active individuals at risk

4. Prevention of Perinatal Transmission

Routine antenatal screening of all pregnant women for HBsAg
HBsAg-positive pregnant mothers identified and managed
Birth dose + HBIG for infants of HBsAg-positive mothers
Antiviral therapy (e.g., Tenofovir) in third trimester for mothers with very high viral load to reduce perinatal transmission risk

5. Infection Control in Healthcare Settings

Universal precautions for all patients (treat all blood/body fluids as potentially infectious)
Proper sterilization/disinfection of instruments
HBV vaccination for all healthcare workers
Safe handling and disposal of sharps
Post-exposure prophylaxis protocols for healthcare workers after needlestick injuries

6. Harm Reduction for IV Drug Users

Needle and syringe exchange programs
Opioid substitution therapy
Counselling and rehabilitation services

7. Health Education

Public awareness about modes of transmission
Promoting safe sex and safe injection behavior
Educating about dangers of unregulated tattooing/piercing
Awareness about HBV vaccination

8. Sterilization and Disinfection

HBV is inactivated by autoclaving (121°C for 20 min), dry heat (160°C for 1 hr)
Effective chemical disinfectants: sodium hypochlorite (bleach), glutaraldehyde, formaldehyde
Proper sterilization of dental and surgical instruments

C. GLOBAL STRATEGY (WHO)

WHO Global Health Sector Strategy on Viral Hepatitis (2016-2021) targets:

90% reduction in new HBV infections
65% reduction in mortality from HBV/HCV

Universal HBV vaccination of all newborns is the single most impactful intervention.

SUMMARY TABLE: Prevention and Control

Category	Measure
Immunization	Universal infant HBV vaccination (birth + 3 doses); catch-up vaccination for unvaccinated adults at risk
Passive immunity	HBIG for newborns of HBsAg+ mothers; post-exposure prophylaxis
Blood safety	Mandatory HBsAg screening of blood donors
Injection safety	Sterile disposable needles/syringes; needle exchange programs
Sexual transmission	Condom use; reduce partner numbers
Perinatal	Antenatal HBsAg screening; birth dose + HBIG
Healthcare	Universal precautions; HCW vaccination
Education	Community awareness; safe behavior promotion

KEY POINTS TO REMEMBER (for exams)

HBV is 50-100 times more infectious than HIV
Incubation period: 45-180 days (average 60-90 days)
HBsAg is the first serological marker to appear; its persistence >6 months = chronic infection
HBeAg positivity = high infectivity
The birth dose within 24 hours is critical for preventing mother-to-child transmission
Combined HBIG + HBV vaccine given to neonates of HBsAg-positive mothers provides >95% protection
HBV vaccine efficacy: 90-95%
HBV is NOT transmitted by feco-oral route
Anti-HBs ≥10 mIU/mL = protective immunity
Chronic HBV is a major risk factor for hepatocellular carcinoma (HCC) and cirrhosis

Source: Park's Textbook of Preventive and Social Medicine (Chapter on Communicable Diseases - Hepatitis B section, pp. 251-256)

This answer covers all components required for a 5-mark university question (3+ handwritten pages) - modes of transmission, specific prophylaxis (vaccine + HBIG with doses/schedule), and comprehensive non-specific prevention and control measures, all sourced from Park's textbook.

This is a shared conversation. Sign in to Orris to start your own chat.